This Cooperative Agreement award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) is supporting the development of a novel "liver digital twin" platform to optimize and improve liver cancer transarterial embolization (TAE) therapies. The $357,939 award to the University of California, Davis will enable the creation of a personalized, patient-specific computational model to simulate and optimize the delivery of TAE, transarterial radioembolization (TARE), and transarterial chemoembolization (TACE) procedures. The virtual liver model will be integrated with an AI-accelerated optimization algorithm to assist physicians in selecting the optimal injection points and dosages for these liver cancer treatments. This project aims to enhance the efficacy and safety of these interventional procedures by enabling more precise and personalized targeting of tumors, ultimately improving patient outcomes.
Generated 3/4/25, 6:11 AM